



12-31-02

03C08

FEES TRANSMITTAL

41A

Application Number 09/717,051  
Filing Date November 20, 2000  
Confirmation No. 2191  
Inventors Michael S. South et al.  
Group Art Unit  
Examiner Name  
Attorney Docket Number PHA 4162.3 (3204/2)

**METHOD OF PAYMENT**

1.  The Commissioner is hereby authorized to charge the indicated fees to Deposit Account No. 19-1345.
- The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 to Deposit Account No. 19-1345.
- Applicant claims small entity status.

2.  Check Enclosed. The Commissioner is hereby authorized to charge any under payment or credit any over payment to Deposit Account No. 19-1345.

**FEES CALCULATION**

1.  BASIC FILING FEE Subtotal (1) \$ \_\_\_\_\_  
(Type: \_\_\_\_\_)

2.  EXTRA CLAIM FEES Subtotal (2) \$ \_\_\_\_\_

Total Claims \_\_\_\_\_  
Independent Claims \_\_\_\_\_  
Multiple Dependent Claims \_\_\_\_\_

3.  ADDITIONAL FEES Subtotal (3) \$ \_\_\_\_\_

- Surcharge - late filing fee or oath
- Surcharge - late provisional filing fee or cover sheet
- Extension for reply within \_\_\_\_\_ month
- Notice of Appeal
- Filing a Brief in Support of an appeal
- Request for ex parte Reexamination
- Petitions to the Commissioner
- Submission of Information Disclosure Statement
- Recording each patent assignment per property
- Request for Continued Examination
- Other: \_\_\_\_\_

**TOTAL AMOUNT OF PAYMENT** \$180.00

  
Kathryn J. Doty, Reg. No. 40,593

12-30-02

Date

KJD/BSS/vlm

Express Mail Label No. EL 945486919 US



PHA 4162.3 (3204/2)  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Michael S. South et al.

Serial No. 09/717,051

Filed November 20, 2000

Confirmation No. 2191

For SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL  
FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE

December 30, 2002

TO THE COMMISSIONER FOR PATENTS,

SIR:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance  
with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the  
\* references listed on the attached PTO/SB/08A for consideration by the Patent and  
Trademark Office in the above-entitled application and to be made of record therein.

Respectfully submitted,

Kathryn J. Doty, Reg. No. 40,593  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400


01/02/2003 YPOLITE1 00000122 09717051  
01 FC:1806 180.00 0P

KJD/BSS/vlm

Express Mail Label No. **EL 945486919 US**

PTO/SB/08A

**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**



Sheet

1

of

2

<i>Complete if Known</i>	
Application Number	09/717,051
Filing Date	November 20, 2000
Confirmation Number	2191
First Named Inventor	Michael S. South
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket No.	PHA 4162.3 (3204/2)

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	59	4,489,096	B1	Terao et al.	12-18-1984
	60	4,851,413	B1	Terao et al.	07-25-1989
	61	4,992,469	B1	Ozawa et al.	02-12-1991
	62	5,304,658	B1	Terao et al.	04-19-1994
	63	5,741,819	B1	Illig et al.	04-12-1998
	64	6,180,627	B1	Blagg et al.	01-30-2001

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
	65	DE	198 51 421	A1	Boehringer Ingelheim Pharma KG	05-11-2000	A
	66	EP	0 354 495	A1	Godecke Aktiengesellschaft	02-14-1990	A
	67	WO	98/09987	A1	Biochem Pharma, Inc.	03-12-1998	
	68	WO	99/43660	A1	Neurogen Corporation	09-02-1999	
	69	WO	99/48892	A1	Merck & Sharp & Dohme Limited	09-30-1999	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

**SUPPLEMENTAL INFORMATION  
DISCLOSURE  
STATEMENT BY APPLICANT**
**Complete if Known**

Application Number	09/717,051				
Filing Date	November 20, 2000				
Confirmation Number	2191				
First Named Inventor	Michael S. South				
Group Art Unit	TBA				
Examiner Name	TBA				
Sheet	2	of	2	Attorney Docket No.	PHA 4162.3 (3204/2)

**OTHER ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	70	COBURN, C.A., "Small-molecule direct thrombin inhibitors 1997-2000." Expert Opinions on Therapeutic Patents, 2001, 721-738, Vol. 11, No. 5	
	71	XP-002182132 - DARVAS, et al., "Investigation of the Common Mechanism of Action of Antibacterial Compounds Containing .gamma.-pyridone-.beta.-carboxylic acid Structure by Principal Component." Arzneim.-Forshc., 1979, pp. 1334-1339, Vol. 29, 9.	
	72	XP-002172033 - KOHAMA et al., "Preparation of Piperidinyloxyacetylaminobenzoylalanine Derivatives and Analogs as Antithrombotics." JP 07,233,148.	
	73	XP-002187583 - MOERNER, Hoppe-Seyler's Z. Physiol. Chem., 69, 1910; 357.	
	74	PATEL et al., "Directed Aminomethylation of 3-Hydroxy-3(1H)-pyridinones and 3-hydroxy-4(1H)-pyridinones: Synthesis of iso-Deferiprone." Tetrahedron, 1996, pp. 1835-1840, Vol. 52, No. 5.	
	75	XP-002182410 - TRECOURT et al., "First Synthesis of (+)-harzianopyridone by Metalation of Polysubstituted O-pyridylcarbamates." J. Heterocycl. Chem., 1995, pp. 1117-1114, Vol. 32, No. 4.	
	76	TULINSKY et al., "Novel Asymmetric Synthesis of Atropisomeric 6-Aryl Pyrazinones via an Unusual Chirality Transfer Process." J. Org. Chem., 1999, pp. 93-100, Vol. 64, No. 1.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document ST.3. <sup>6</sup>Applicant is to place a check mark here if English language Translation by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.